Demographic and baseline characteristics of the patients

Patient CharacteristicsALL patients(Number (percent))
Total no. of patients30 (100)
Median age, years (range)55 (26–74)
Sex
 Female8 (27)
 Male22 (73)
Metastatic stage (n)
 M01 (3)
 M1a6 (20)
 M1b6 (20)
 M1c17 (57)
Lactate dehydrogenase
  ≤ ULNa20 (67)
  > ULN10 (33)
ECOG
 019 (63)
 111 (37)
Primary site
 Cutaneous24 (80)
 Mucosal2 (7)
 Ocular3 (10)
 Unknown primary1 (3)
BRAF status
  BRAF mutated (V600E)9 (30)
  BRAF wild type21 (70)
Prior therapies**
 Prior adjuvant therapy5 (17)
 Prior therapy with a BRAF inhibitor6 (20)
Brain metastases
 Patients without brain metastases26 (87)
 Patients with brain metastases4 (13)

aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks a of Temozolomide